Weiwei Tan

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge et al. · New England Journal of Medicine · 2010 · 4.5K citations

Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer

Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

Daniel B. Costa, Susumu Kobayashi, Shuchi S. Pandya et al. · Journal of Clinical Oncology · 2011 · 587 citations · Full text

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

Sai‐Hong Ignatius Ou, Eunice L. Kwak, Christina T. Siwak-Tapp et al. · Journal of Thoracic Oncology · 2011 · 433 citations

Tumor Biology, Oncology, Medicine +11

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

Patricia LoRusso, Smitha Krishnamurthi, John J. Rinehart et al. · Clinical Cancer Research · 2010 · 247 citations